Call For Europe-Wide Drug Assessment
European public-sector health insurance funds must agree a unifiedstrategy with drug companies to achieve a unified procedure for the evaluation of new, innovative drugs, Wolfgang Schmeinck, president of the German federation of industrial health funds, has said.
The European Union drug approval system now provides firms with an EU dimension to pricing and volume sales policy, he said; new drugs come onto EU markets at a unified price. But, he added, the price demanded often bears little relation to manufacturers' costs nor correspond to the degree of innovation claimed.
In Germany, he said, 1.2 billion Deutschemarks ($685.5 million) of the 1.6 billion marks' growth in drug spending is due to prescribing of "genuinely or reputedly innovative drugs" instead of more cost-effective, older products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze